Search
01/06/2025
EFFECT OF RITUXIMAB ON NEUROFILAMENT IN CIDP: DATA FROM THE CIDPRIT RANDOMIZED CONTROLLED TRIAL
Gallo, C, Doneddu, PE, Collet-Vidiella, R, Cocito, D, Manganelli, F, Falzone, Y, Pinter, GL, Benedetti, L, Mazzeo, A, Peci, E, Spina, E, Strano, C, Dalla Bella, E, Germano, F, Gentile, L, Liberatore, G, Cutellè, C, Bianchi, E, Querol, L, Nobile-Orazio, E. EFFECT OF RITUXIMAB ON NEUROFILAMENT IN CIDP: DATA FROM THE CIDPRIT RANDOMIZED CONTROLLED TRIAL. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025
EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS
Allen, JA, Door, PAV, Benedetti, L, Basta, I, Dysgaard, T, Eggers, C, Guptill, JT, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, TN, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025
Clinical spectrum of anti-IgLON5 disease: A case series with three distinct movement disorder phenotypes
Alberti-Vall, B, Olmedo-Saura, G, Domine, M, Borrell-Pichot, M, Avila, MC, Jordana, AV, Pagonabarraga-Mora, J, Kulisevsky, J, Perez, P. Clinical spectrum of anti-IgLON5 disease: A case series with three distinct movement disorder phenotypes. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025
Fast-track strategy to shorten hospital stay in acute complicated paediatric appendicitis: protocol of the FTAA clinical trial
Leganes, C, Zapata, MJM, Valle, JM, Membrilla, E, Bordon, EA, Palazón, P, Fortes, LM, Núñez, B, Alvarez, N, Pueyo, C, Soria, A, Oviedo, M, Delgado-Espinoza, CE, Antonijoan, RM. Fast-track strategy to shorten hospital stay in acute complicated paediatric appendicitis: protocol of the FTAA clinical trial. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).
01/06/2025
Non-commercial sponsored clinical trials with medicinal products in Spain since CTIS implementation
Delgado-Espinoza, CE, Garcia, CP, Hosey, KA, Pestana, MJC, Lasso, LFC, Arbos, RMA. Non-commercial sponsored clinical trials with medicinal products in Spain since CTIS implementation. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).
01/06/2025
Environmental impact of avoidable tertiary care: earth-caring arguments for decentralizing trials
Pontes, C, Cortes, M, Delgado, CE, Castillo, LF, Amaro, K, Torres, F, Antonijoan, RM. Environmental impact of avoidable tertiary care: earth-caring arguments for decentralizing trials. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).